Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Patent
1997-08-29
1999-07-27
Eisenschenk, Frank C.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
4241331, 4241411, 4241421, 530350, A61K 39395, A61K 3940, A61K 3942, C07K 100
Patent
active
059286415
ABSTRACT:
A monoclonal antibody, or fragments thereof, having binding specificity for both endoglin expressed on human vascular endothelial cells and on murine endothelial cells. Antiangiogenic therapy in mammals can be effected by administering to the mammalian host a therapeutically effective amount of an anti-endoglin monoclonal antibody, or fragment thereof, which is conjugated to at least one angiogenesis inhibitor or antitumor agent. The composition is useful for treating tumor and angiogenesis-associated diseases.
REFERENCES:
patent: 5407805 (1995-04-01), Seon
patent: 5776427 (1998-07-01), Thorpe et al.
Burrows, et al, "Up-regulation of endoglin on . . . " Clin. Can. Res. 1:1623-1634, 1995.
Haruta, et al, "Distinct human leukemia . . . " PNAS 83:7898-7902, 1986.
Seon, et al, "Monoclonal antibody that defines . . . " PNAS 80:845-849, 1983.
Jonathan M. Austyn and Kathryn J. Wood, "Principles of Cellular and Molecular Immunology", pp. 37 and 38, 1993.
Pharmingen biological reagents catalog, p. 43.
Eisenschenk Frank C.
Health Research , Inc.
Nelson Brett
LandOfFree
Anti-endoglin monoclonal antibodies and their use in antiangioge does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-endoglin monoclonal antibodies and their use in antiangioge, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-endoglin monoclonal antibodies and their use in antiangioge will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-875939